INVA
InnovivaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Q1 showed resilient operating momentum, ample liquidity, and active buybacks, while NUZOLVENCE still has a second-half-2026 availability window; if the launch lands and IST keeps compounding, the mixed royalty-plus-specialty model can support a higher multiple [#IR-2026-05-06].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.4.
What can break
Capital-allocation support from buybacks is helpful, but it may not fully offset weakness in core earnings drivers.
Momentum
34
Value
71
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $33.20 · Bear $16.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $33.20
Why
Momentum34 · Δ7d -6.6
Value71 · Δ7d +0.4
Sentiment63 · Δ7d +8.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
34
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
-7.2
Value
71
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.8
Sentiment
63
33% active weight
Current posture
7d trendImproving
Δ7d
+8.2
Δ21d
+3.7
Why this grade
Composite grade C. Momentum 34.0 / Value 70.8 / Sentiment 62.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.59B
Beta
0.44
Shares Out
74.77M
P/E (TTM)
15.5
P/S (TTM)
3.85
P/FCF (TTM)
7.58
Rev YoY
+20.4%
EPS YoY
+5391.4%
Gross Margin
+81.5%
Op Margin
+43.2%
Net Debt
$35.85M
Current Ratio
14.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology